VistaGen Therapeutics(US:VTGN) Globenewswire·2026-01-19 17:00Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from April 1, 2024, to December 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Vistagen securities during the specified Class Period [2]. - The Complaint alleges that Defendants made materially false and misleading statements regarding the development of fasedienol and the Phase 3 PALISADE‑3 trial, which faced significant adverse facts [3]. - Defendants are accused of disseminating false information and concealing material adverse data about the PALISADE‑3 study's design, execution, and clinical results [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by March 16, 2026, although sharing in any recovery does not require serving as lead plaintiff [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].